Radioactive dye

PreclinicalSmall molecule

MMassachusetts General Hospital

Radioactive dye is one of 25 small molecule programs targeting Sciatica. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SciaticaActive, not recruiting

SciaticaPreclinical

Active, not recruiting

Competition

Competitive Landscape

27 competitors in Sciatica

#DrugCompanyPhaseTrials

Aleve

Alnylam Pharmaceuticals

Approved

1 2

Medrol

Pfizer

Approved

1 3

Decadron

AAspen Global Incorporated

Approved

2 4

Oruvail

WWyeth-Lederle Vaccines

Approved

1 5

Advil

KKenvue Brands

Approved

1 6

Demerol

Paracetamol

1 8

Vimpat

UCB

Phase 3

1 9

Pred Forte

Novartis

Phase 3

1 10

Rayos

RRoxane Laboratories

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sciatica1 trial

PET/MRI Imaging of Neuraxial Inflammation in Sciatica Patients

Completed·MMassachusetts General Hospital··NCT02130271·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Radioactive dye. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Radioactive dye compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Radioactive dye. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMassachusetts General Hospital

Radioactive dye

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Sciatica1 trial

References

Drug Info

Quick Facts

Related News